| Gene Symbol | RELN |
| Full Name | Reelin |
| Chromosome | 7q22.1 |
| Protein Type | Signaling Protein |
| Target Class | Signaling Protein |
| Function | The protein contains an N-terminal signal peptide followed by 8 reelin repeat domains (R1-R8), each approximately 350 amino acids in length. |
| Mechanism of Action | Drugs targeting RELN would primarily work by enhancing reelin expression or signaling through its receptors (VLDLR and ApoER2) to promote neuronal migration, synaptic plasticity, and cognitive function. Alternatively, pathway modulators could enhance downstream signaling cascades (Dab1-mediated pathways) to compensate for reelin deficiency or dysfunction. |
| Primary Expression | migrating neurons and mature neurons, VLDLR mediates reelin signaling involved in neuronal positioning and synaptic function [4](https://pubmed |
| Druggability | Low (0.33) |
| Clinical Stage | Approved |
| Molecular Weight | 400 kDa |
| Amino Acids | 350 aa |
| Pathways | Epigenetic, Reelin-Mediated Cytoskeletal Stabilization Protoco |
| UniProt ID | P78509 |
| Ensembl ID | ENSG00000189056 |
| GeneCards | RELN |
| Human Protein Atlas | RELN |
| Associated Diseases | AD, Als, Alzheimer, Alzheimer disease |
| Known Drugs/Compounds | valproic acid |
| Interactions | AD, ALZHEIMER, ALZHEIMER'S DISEASE, AMYLOID, APOE, APOE3 |
| SciDEX Target | View Target Profile (9 clinical trials) |
| SciDEX Hypotheses | Reelin-Mediated Cytoskeletal Stabilization Protoco Reelin Signaling Enhancement |
| KG Connections | 295 knowledge graph edges |
| Databases | GeneCardsNCBI GeneHPASTRING |
No AI portrait yet
No comments yet. Be the first to comment!